Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock Has Consensus Price Target of $67.67

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have received a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and four have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $67.67.

A number of research analysts have recently weighed in on the company. Piper Sandler increased their price target on Scholar Rock from $60.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, September 15th. Jefferies Financial Group raised their price target on Scholar Rock from $57.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Citigroup lifted their price objective on Scholar Rock from $60.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. UBS Group reiterated a “buy” rating on shares of Scholar Rock in a report on Tuesday, September 15th. Finally, Evercore reissued an “outperform” rating and issued a $72.00 target price on shares of Scholar Rock in a research note on Tuesday, September 15th.

Scholar Rock Price Performance

Scholar Rock stock opened at $40.64 on Friday. The business’s 50-day simple moving average is $51.00 and its 200 day simple moving average is $49.91. The stock has a market cap of $4.95 billion, a price-to-earnings ratio of -11.78 and a beta of 0.61. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $61.76. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting the consensus estimate of ($0.84). During the same period in the prior year, the firm earned ($0.98) EPS. As a group, research analysts anticipate that Scholar Rock will post -3.23 earnings per share for the current year.

Hedge Funds Weigh In On Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in Scholar Rock by 20.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after buying an additional 242 shares during the period. Values First Advisors Inc. lifted its holdings in Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after acquiring an additional 286 shares in the last quarter. Syon Capital LLC grew its stake in Scholar Rock by 6.4% in the second quarter. Syon Capital LLC now owns 9,782 shares of the company’s stock valued at $538,000 after acquiring an additional 588 shares during the period. PNC Financial Services Group Inc. grew its stake in Scholar Rock by 92.4% in the first quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company’s stock valued at $62,000 after acquiring an additional 610 shares during the period. Finally, Allworth Financial LP acquired a new position in Scholar Rock in the second quarter valued at about $35,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company’s approach is designed to modulate biologic pathways in specific tissues while potentially limiting effects elsewhere in the body.

Scholar Rock’s lead product candidate is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that negatively regulates muscle growth.